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Abstract
The matrix metalloproteinases (MMPs) gelatinase A (MMP-2) and gelatinase B (MMP-9) are mediators of brain injury in multiple sclerosis (MS)
and valuable biomarkers of disease activity. We applied bidimensional zymography (2-DZ) as an extension of classic monodimensional zymog-
raphy (1-DZ) to analyse the complete pattern of isoforms and post-translational modifications of both MMP-9 and MMP-2 present in the sera
of MS patients. The enzymes were separated on the basis of their isoelectric points (pI) and apparent molecular weights (Mw) and identified
both by comparison with standard enzyme preparations and by Western blot analysis. Two MMP-2 isoforms, and at least three different iso-
forms and two different states of organization of MMP-9 (the multimeric MMP-9 and the N-GAL-MMP-9 complex) were observed. In addition,
2-DZ revealed for the first time that all MMP-9 and MMP-2 isoforms actually exist in the form of charge variants: four or five variants in the N-
GAL complex, more charge variants in the case of MMP-9; and five to seven charge variants for MMP-2. Charge variants were also observed in
recombinant enzymes and, after concentration, also in sera from healthy individuals. Sialylation (MMP-9) and phosphorylation (MMP-2) con-
tributed to molecular heterogeneity. The detection of charge variants of MMP-9 and MMP-2 in MS serum samples illustrates the power of 2-DZ
and demonstrates that in previous studies MMP mixtures, rather than single molecules, were analysed. These observations open perspectives
for better diagnosis and prognosis of many diseases and need to be critically interpreted when applying other methods for MS and other
diseases.
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Introduction
Multiple sclerosis (MS) is a multifactorial, chronic and debilitating
disease of the central nervous system (CNS), mostly in young adults
[1]. Its pathogenesis has all the characteristics of neuroinflammatory
and autoimmune diseases, as it involves the attack by autoreactive T
cells, B lymphocytes, macrophages and microglial cells against brain
white matter [2, 3].
The pathological hallmarks of MS lesions are perivascular inflam-
mation, breakdown of the blood–brain barrier (BBB), variable axonal
and oligodendrocyte damage, focal demyelination and scar formation
[4–6]. Myelinotoxic factors include antibodies, activated complement,
cytokines, reactive oxygen species (ROS) and matrix metalloprotein-
ases (MMPs).
Matrix metalloproteinases are interesting because they are impli-
cated in a variety of physiological and pathological processes. On one
hand, they regulate neurogenesis, oligodendrogenesis and brain plas-
ticity in developing healthy brain. On the other hand, they are involved
in neurodegenerative, vascular and inflammatory disorders [7, 8].
The 25 human MMPs are calcium-activated and Zn2+-dependent,
extracellular or membrane-bound endopeptidases with different
structural and functional domains. Matrix metalloproteinases modu-
late cell–cell and cell–extracellular matrix (ECM) interactions and
appear to have a regulatory role in cell signalling, because they are
able to process growth factors, receptors, hormones, adhesion
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molecules, cytokines and chemokines. This means that the mecha-
nisms by which MMPs influence cell activity in normal or pathological
conditions are complex and different, and this makes it even more dif-
ficult to obtain their therapeutic inhibition in a precise way [9].
Because of the relevance of MMPs as regulatory enzymes in
health and disease, it is important to understand how they are regu-
lated in different conditions. In general, inducible MMPs are regulated
at the transcriptional level by growth factors, chemokines, cytokines
and ROS, and also by dietary molecules [10, 11]. Subsequent post-
translational modification of the inactive zymogen (pro-enzyme) is
obtained by removal of the pro-peptide domain to expose the active
catalytic site (active enzyme). Following activation, MMPs are modu-
lated by physiological inhibitors, i.e. the tissue inhibitors of matrix
metalloproteinases (TIMPs) and a2 macroglobulin in plasma [12,
13]. In the course of MS, up-regulation of inducible MMP-9/gelati-
nase B increases the permeability of the BBB, facilitates the infiltration
of leucocytes into the CNS, degrades the myelin sheath (e.g. myelin
basic protein), and causes neuronal damage [3, 7, 8, 14–16]. On
these grounds, elevation of MMP-9 in serum and CSF has been
considered a biomarker of disease activity [17–20] and a therapeutic
target for MS [7, 21–23].
However, the role of MMP-9 in MS is complex: it involves dif-
ferent forms, multiple locations, different producer cell types, sev-
eral mechanisms of intervention at different stages of disease, and
different substrate specificities. For example, MMP-9 might have
opposite effects on the disease. It degrades myelin constituents
(directly or indirectly) in MS pathogenesis in the early stage of the
disease, and contributes to remyelination in later stages, as oligo-
dendrocytes might use MMP-9 to facilitate membrane process
extensions [24].
Different forms of MMP-9 have been described, for instance, the
inactive zymogen pre–pro-enzyme containing the signal peptide [25,
26], and the pro-enzyme pro-MMP-9 of 92 kD. Serum pro-MMP-9
may be found covalently associated with NGAL (Neutrophil Gelati-
nase–Associated Lipocalin, or Lipocalin-2 [25 kD]). The activation of
pro-MMP-9, mainly by MMP-3 [27], occurs by removal of the N-ter-
minal pro-peptide, yielding the 82 kD MMP-9 that is inhibited by its
specific natural inhibitor TIMP-1. Carboxyterminal cleavage yields the
65 kD MMP-9, which is not inhibited by TIMP-1 [28–31]. Because of
its molecular weight, very close to that of MMP-2, the 65 kD MMP-9
may be confused with an activated form of MMP-2 of about 68 kD.
Finally, multimeric forms of MMP-9 have been described [32, 33].
The finding that MMP-9, as other MMPs, also cleaves intracel-
lular substrates, and shows different responsiveness to inflamma-
tory molecules and therapeutic inhibitors depending on cell type
and location, greatly complicates our understanding of the roles of
MMP-9 in MS. For instance, it is not excluded that the cleavage of
intracellular substrates, such as crystallins, contributes to the path-
ogenesis of MS [34–36]. The accessibility of intracellular substrates
to principally extracellular proteolysis may occur when cells suc-
cumb by apoptosis, necrosis or any other type of cellular disinte-
gration [37]. The analytical methods presently available for
detecting gelatinases can describe only some of their specific prop-
erties, i.e. either gelatinase mRNA, or protein levels, expression and
activity of gelatinases at the cellular level, but not one of the com-
monly used methods allows to distinguish post-translational modifi-
cations of the gelatinase isoforms (the charged variants in this
article). Monodimensional (1-D) zymography does not provide
information regarding the gelatinase variants produced by post-
translational modifications. For example, classical zymography on
gelatin-embedded gels reveals both the pro-form (the latent zymo-
genic form) and activation forms of gelatinases and shows the
molecular mass diversity of their isoforms, but does not show any
diversity if their molecular mass is similar, as may be the case for
the 65 kD MMP-9 variant and the activation forms of MMP-2 [38].
It is known that MMP-9 can be either glycosylated, sialylated or
nitrosylated, whereas MMP-2 may be phosphorylated [38–40].
Detection of gelatinase variants – i.e. the post-translationally mod-
ified isoforms of gelatinases – is essential to merge a more complete
scenario of gelatinases in the course of MS.
At present, some information on gelatinase variants can be
obtained by bidimensional (2-D) gel electrophoresis and proteomic
analysis, but this approach is useful only when proteins collected
from biological fluids are purified and concentrated before the appli-
cation to the gel [41].
Here, we have refined the zymographic methodology to analyse
the gelatinases present in the sera of patients with RR-MS by using
2-D zymography (2-DZ). Bidimensional zymography, which is based
on isoelectrofocusing (1st dimension) and SDS gel electrophoresis
on gels copolymerized with gelatin (2nd dimension), offers a more
complete pattern of gelatinolytic enzymes, which are separated on the
basis of their different isoelectric points (pI) and apparent molecular
weights (Mw).
Materials and methods
Patients
Sera from 10 healthy controls (HC; six females, four males) and 33
patients with relapsing-remitting MS (RR-MS; 21 females, 12 males).
All patients – 22 with RR-MS in remission phase (inactive RR-MS), 11
in relapse phase (active RR-MS) – were from Southern Italy. Patients
were judged to have active disease according to clinical criteria and
radiological evidence of some exacerbation, appearance of a new symp-
tom or worsening of an existing symptom attributable to MS, accompa-
nied by an appropriate new neurologic abnormality. All sera were
obtained from the Hospitals ‘San Carlo’ (Potenza, Italy) and ‘Madonna
delle Grazie’ (Matera, Italy) following the approval of the ‘Ethics Com-
mittee for Experimentation’ in Potenza (Resolution No. 132, 29 January
2008). Patients gave their informed consent and were treated indepen-
dently from this study. All zymographic analyses shown in this paper
were from RR-MS sera of patients not subjected to therapy.
Detection of gelatinases by 1-D (1-DZ) and 2-D
gelatin zymography (2-DZ)
Gelatinases present in the sera from MS patients or from HC were
detected by SDS-PAGE gelatin zymography. Monodimensional scanning
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densitometry was used on an Image Master 1D program (Pharmacia
Biotech, Uppsala, Sweden) platform. Levels of different gelatinase iso-
forms were expressed as optical density (OD) 9 mm2.
Gelatinase isoforms and charge variants present in the sera from MS
patients or from HC were detected by 2-D gelatin zymography [42].
Specifically, samples were applied under non-reducing conditions. Aliqu-
ots of 25 or 35 ll of sera were mixed with the rehydration solution
containing 7 M urea, 2 M thiourea, 2% CHAPS (w/v), 0.5% (v/v) immo-
bilized pH gradient (IPG) buffer, plus a trace of bromophenol blue, to a
final volume of 250 ll. Isoelectrofocusing (IEF) was performed on IPG
Dry-Strips of 13 cm with a linear pH gradient of four to seven or with a
non-linear pH gradient of three to 11 (GE-Healthcare, Uppsala, Sweden).
Immobilized pH gradient Dry-Strips were rehydrated with a sample-con-
taining rehydration solution for 12 hrs at 20°C. Isoelectrofocusing was
run by using an IPGphor unit (Amersham Biosciences, Uppsala, Swe-
den) at 20°C for a total of 36450 Vh. After IEF, IPG-strips were equili-
brated for 20 min. by gentle shaking in equilibration buffer: 6 M urea,
30% (w/v) glycerol, 2% (w/v) SDS, 50 mM Tris-HCl (pH 8.8). In the
second dimension, proteins were separated in a 7.5% or 8.5% (w/v)
polyacrylamide gel copolymerized with 0.1% (w/v) gelatin on the SE
600 Hoefer System at 4°C first for 30 min. at 180 V and then for 5 hrs
at 240 V. HMW-SDS Marker kits (Amersham Biosciences) or Precision
Plus, Protein Standards Dual Color (Bio-Rad, Segrate, Italy) were used
as molecular weight markers. After electrophoresis, for the development
of enzymatic activities, gels were washed two times in washing buffer
and then incubated for 14 hrs at 37°C in developing buffer. Gels were
then stained with Coomassie Brilliant Blue R-250 (for 30 min. at room
temperature) and destained in methanol/acetic acid/H2O. The 2-DZ gels
were scanned by using a ScanMaker 9800 XL-Microtek (Hsinchu, Tai-
wan). The images were digitally converted from positive to negative
images. Image analysis for the determination of apparent Mw and pI
was carried out by using the ImageMaster 2D Elite V. 2002.01 software
(Amersham Biosciences) and enzyme levels were expressed as Spot Vol-
ume (corresponding to the sum of pixel intensities within the digested
spot). The individual digested spot volumes were normalized as a
percentage of the total volume of all digested spots present in the gel.
Purification of gelatinases by gelatin affinity
chromatography
Gelatinase purification was performed by miniature gelatin affinity chro-
matography [43]. Briefly, 0.5 ml of pooled RR-MS sera, diluted with
0.5 ml of 50 mM Tris pH 7.5, 0.6 M NaCl (equilibration buffer), were
added to mini-spin columns (Bio-Rad Laboratories) loaded with 0.5 ml
gelatin-Sepharose 4B beads (GE Healthcare, Uppsala, Sweden; 1/3 beads
in 2/3 equilibration buffer) previously equilibrated with two volumes of
equilibration buffer. The mixture was then equilibrated at 4°C for 60 min.
(vortexing every 10 min. and reversing the column).
Successively, the cap was removed and the unbound sample was
removed by centrifugation at 3000 9 g (Amicon MC-13 microcentri-
fuge; Millipore, Bedford, MA, USA), for 2 min. Beads were washed two
times with washing buffer 50 mM Tris pH 7.5, 0.1 M NaCl, and gelatin-
ases were eluted with 150 ll of 5% DMSO in 50 mM Tris pH 7.5,
0.1 M NaCl after incubation for 30 min. at room temperature. The elu-
ate was totally recovered by centrifugation at 2000 rpm for 2 min., and
then desalted and concentrated to a final volume of 30 ll with 2.0 ml
of water in Vivaspin 500 (MWCO 30,000; GE Healthcare). Gelatinase
levels present in the purified fraction (corresponding to the pooled RR-
MS sera) were analysed by 2-D gelatin zymography.
Desialylation
To 20 ll of purified gelatinases obtained from 10 pooled RR-MS sera,
were added 5 ll of reaction buffer and 5 ll (0.5 U/ll) of a(2-3,6,8,9)
neuraminidase from Arthrobacter ureafaciens (N 3786; Sigma-Aldrich,
Sigma, St. Louis, MO, USA). Digestions were performed at 37°C for
6 hrs. The samples were then diluted with 220 ll of the rehydrating
solution of the IPG strips and the desialylated fraction was analysed by
2-DZ as described above.
Western blot analysis
After electrophoretic (E) runs 1-DE or 2-DE, gels without gelatin substrate
were rinsed in transfer buffer and blotted on a nitrocellulose membrane
(for 90 min. at 350 mA), using a MINI-trans Blot apparatus (Bio-Rad Lab-
oratories). After transfer, the membranes were incubated with primary
antibodies: Anti-MMP-9 (Ab-8) Mouse mAb (IA5) at concentration of
2.66 lg/ml (recognizes the 92 kD latent and the 86 kD active forms),
Anti-MMP-2 (Ab-4) Mouse mAb (75-7F7) at concentration of 1.0 lg/ml
(Calbiochem, Milano, Italy; recognizes the 72 kD latent and the 66 kD
active forms), Anti-MMP-9 (4A3) at concentration of 2.0 lg/ml (Novus
Biologicals, Novus Biologicals, Segrate, MI, Italy; recognizes the 82 kD
and the 65 kD active forms) and Anti-NGAL Antibody (5G5) at concentra-
tion of 2.0 lg/ml (EuroClone, Pero, MI, Italy; recognizes the human
NGAL). Thereafter, the membranes were incubated with the HRP-labelled
secondary antibody (anti-mouse, Invitrogen, San Giuliano Milanese, MI,
Italy or Sigma-Aldrich). Finally, detection was carried out with ECL reagent
(GE Healthcare) for detection on X-ray film (Fuji RX). Images were
acquired by using a ScanMaker 9800 XL-Microtek.
Concanavalin A chromatography
To distinguish the 65 kD MMP-9 from of MMP-2, RR-MS serum, con-
centrated by affinity chromatography on gelatin-Sepharose, was purified
by concanavalin-A-Sepharose affinity chromatography (Sigma-Aldrich)
according to the manufacturer with minor modifications.
Briefly, a mini-spin column with 500 ll of concanavalin-A-Sepharose
was pre-washed with five column volumes of wash solution (1 M NaCl,
5 mM MgCl2, 5 mM MnCl2, 5 mM CaCl2) and equilibrated with 20 mM
Tris, pH 7.4, 0.5 M NaCl (equilibration buffer).
A volume of 75 ll of concentrated RR-MS sera, diluted with 225 ll of
equilibration buffer, was added to mini-spin columns, the mixture was
then incubated at 4°C for 60 min. (vortexing every 10 min. and reversing
the column). After sample application, the unbound fraction was recov-
ered by centrifugation (pass through) and the column was washed first
with 300 ll of equilibration buffer and then with 50 mM methyl a-
D-mannopyranoside in equilibration buffer. Finally, the column was
eluted with the equilibration buffer containing 0.5 M methyl a-D-manno-
pyranoside. Successively, the fractions were desalted and concentrated
to a final volume of 30 ll with 2.0 ml of water in Vivaspin 500 (MWCO
10,000; GE Healthcare) and then analysed by gelatin 2-D zymography.
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Results
Analysis of serum samples by 1-D zymography
(1-DZ)
The proteolytic profile of serum samples from patients with relaps-
ing-remitting (RR) MS was analysed by using classical mono-
dimensional zymography in non-reducing conditions. A representative
zymogram of a serum sample from a RR-MS patient is shown in Fig-
ure 1 (lane 1). Resulting bands were compared with two different
MMP-9 standard preparations (lanes 2 and 3). The standard applied
on lane 2 was an insect-derived human recombinant MMP-9 [44],
whereas the standard applied on lane 3 was a human recombinant
MMP-9 produced in Chinese hamster ovary (CHO) cells (Calbio-
chem). The standard bands 2A, 2B and the broad band 3AB corre-
sponded to the multimeric forms of MMP-9; bands 2C and 3C
corresponded to pro-MMP-9; bands 2D and 3D corresponded to the
activation forms of MMP-9; and finally the lower 3E band (present
only in the Calbiochem Standard) of about 50 kD probably corre-
sponded to an autolytic fragment.
When comparing the MMP-9 standard profiles shown in lanes 2
and 3 with the gelatinase profile present in the RR-MS serum (lane
1), we noticed that the main band of the standards and serum
migrated with different mobilities. The band 1F of ~68 kD corre-
sponded to MMP-2. In this respect, it should be mentioned that 1-DZ
is routinely applied for the analysis of gelatinases in biological fluids
and the assignment of the zymographic bands to either gelatinases A
or B has been confirmed many times.
Lane HC shows a HC serum. In healthy individuals, only pro-
MMP-9 (band A) and MMP-2 (band B) are present. The MMP levels
in HC sera were always lower than in MS sera, as can also be deduced
from this figure. Additional bands are present only in some MS sera:
in particular two bands around 170 and 120 kD (an example of the
latter is the band 1C in Fig. 1) corresponding to the covalent MMP-9/
NGAL complex.
Identification of gelatinases by Western blot
analysis
The identification of gelatinases by Western blot was first carried out
by 1-D zymographic and electrophoretic analyses. In view of the fact
that zymographic analysis has a sensitivity in the picogram range,
whereas Western blot analysis has a sensitivity in the nanogram
range, we concentrated the samples prior to Western blot analysis.
Fivefold concentrated (Vivaspin 500, MWCO 50,000; GE Health-
care) serum samples from either HC or RR-MS patients were sub-
jected to 1-DZ and 1-DE. The latter were transferred on nitrocellulose
membrane and treated with different antibodies, as described in the
materials and methods section.
As shown in Figure 2, in the control (HC) sample, only the 92 kD
pro-MMP-9 and the MMP-2 bands were detected, whereas, in the
RR-MS sample, three additional bands were present, corresponding
to the MMP-9 multimeric form, the NGAL-pro-MMP-9 complex, and
the 65 kD MMP-9 form, respectively. The increase in brightness and
importance of the 92 kD MMP-9 band in RR-MS in comparison with
the control is a result of the appearance of a 4th band corresponding
to the activated 82 kD MMP-9 form, that can hardly be distinguished
in 1-DZ, but will become visible in 2-DZ.
Analysis of serum samples by 2-D zymography
and Western blot
1-DZ analysis provides important information on the presence of gel-
atinases in serum samples, but the nature of this information is lim-
ited because it is restricted to Mw differences. Post-translational
isomeric forms with the same Mw might be detected only by applying
an isoelectric focusing step (fractionation on the basis of different
isoelectric points/pIs), as is the case with 2-DZ.
The 2-DZ profiles of gelatinases present in control (HC) and in
RR-MS samples are shown in Figure 3 [panels A and B, respectively
(on the left)]. On the right panels A’ and B’, we show the corre-
sponding Western blot analyses, obtained after the transfer on
nitrocellulose membranes from the 2-DE gel and after treatment with
anti-pro-MMP-9 antibody.
The higher acrylamide percentage (8.5%) applied in this analysis
allowed a better separation of pro-MMP-9 from the activated 82 kD
MMP-9. From top to bottom, five groups of spots were detected: (i )
the multimeric form of pro-MMP-9 (Mw: <200; pI 4.2–4.5); (ii ) the
NGAL-pro-MMP-9 complex (Mw 116 and pI range 5.6–5.9); (iii ) the
pro-MMP-9, represented by a broad lysis zone around Mw 90–92; (iv )
the activated MMP-9 of about 80–82 kD, and pI 4.2–4.4; and finally, a
group of spots corresponding to MMP-2 (Mr 68 kD and pI range 4.9–
5.2). The detection of the 65 kD MMP-9 form observed in 1-DZ was
not well detected in this gel and will be shown later in another gel.
Fig. 1Monodimensional zymography (1-DZ) on 7.5% polyacrylamide
containing 0.1% gelatin. Lane HC: 2 ll of serum from healthy control;
Lane 1: 2 ll of serum from a patient with inactive RR-MS; Lane 2:
10 ng of recombinant human proMMP-9 produced in insect cells; Lane
3: 10 ng human recombinant pro-MMP-9 produced in CHO cells.
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Fig. 2 1-DZ analysis and identification of gelatinases by Western blot. 1.5 ll of serum from healthy control (HC) or from a patient with inactive RR-MS
were loaded on a 7.5% polyacrylamide gel copolymerized with 0.1% (w/v) gelatin (1-DZ). For Western blot analysis, 2 ll of fivefold concentrated (Viva-
spin 500, MWCO 50,000; GE Healthcare) serum samples (the same as in 1-DZ) were separated on a 7.5% polyacrylamide gel without gelatin (1-DE),
transferred on nitrocellulose membranes and incubated with the following primary antibodies: Anti-NGAL Antibody (5G5) at concentration of 2.0 lg/ml;
Anti-MMP-9 (Ab-8) Mouse mAb (IA5) at concentration of 2.66 lg/ml; Anti-MMP-2 (Ab-4) Mouse mAb (75-7F7) at concentration of 1.0 lg/ml and Anti-
MMP-9 Ab (4A3) at concentration of 2.0 lg/ml. Standard Proteins (SP): Precision Plus Protein Standards Dual Color (Bio-Rad).
Fig. 3 2-DZ analysis and identification of
MMP-9 by Western blot. Left panels (A
and B): 2-D zymography (2-DZ) of serum
samples from healthy control (A) and
from an inactive RR-MS patient not sub-
jected to therapy (same patient as in
Fig. 2; B). For 2-DZ, aliquots of 35 ll of
serum were resuspended in the rehydra-
tion solution and subjected to isoelectro-
focusing (IEF; 1st dimension) on IPG Dry-
Strips of 13 cm in a linear pH gradient of
4–7. After IEF, IPG strips were equili-
brated and then applied for the 2nd
dimension in a 8.5% (w/v) polyacrylamide
gel copolymerized with 0.1% (w/v) gelatin.
The isoforms and charge variants of
MMP-2 and MMP-9 appear as clear spots
of digestion on the dark background of
the gel. Right panels (A’ and B’) represent
Western blot analysis of the same sera
shown in A and B. Aliquots of 35 ll of
serum samples (instead of the usual
20 ll) were subjected to 2D electrophore-
sis (2-DE) by using 8.5% (w/v) polyacryl-
amide gels without gelatin. After transfer
of the proteins, the nitrocellulose mem-
branes were incubated with an anti MMP-9
(Ab-8) Mouse mAb (IA5) at concentration
of 2.66 lg/ml.
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The charge variants of gelatinases
As shown for the first time by 2-DZ, all gelatinase isoforms consisted
of a number of charge variants. Matrix metalloproteinases-2: 5-7
charge variants. Matrix metalloproteinases-9: four charge variants in
the NGAL-pro-MMP-9 complex, six charge variants for the 65 kD
MMP-9 (shown later), and several unresolved and undefined charge
variants in the case of multimeric MMP-9, pro-MMP-9, and activated
82 kD MMP-9.
In the HC (panel A), only the pro-MMP-9 and MMP-2 forms were
detected, whereas the lytic spots corresponding to the multimeric
form of pro-MMP-9, the NGAL-pro-MMP-9 complex and the MMP-9
activated forms were not present.
Western blot analyses, carried out with anti-pro-MMP-9 antibody
(right panels), were in agreement with those observed in 1-DZ analy-
sis (Fig. 2). Western blot with anti-NGAL, anti-MMP-2 and anti-65 kD
MMP-9 will be shown in forthcoming gel examples.
Are the charge variants of MMPs due to post-
translational modifications?
Detection of sialylated MMP-9 forms and desialylation
To detect whether the broad lysis areas in the acidic region between
4.2 and 4.4 can be ascribed to the presence of sialic acid, serum sam-
ples from four different patients with RR-MS were enriched and con-
centrated by affinity chromatography on gelatin-Sepharose, as
described in the materials and methods section.
The detection of the sialylated forms of MMP-9 was made easier
after concentration of the sera ten times. By contrast, in HC, this
broad lysis area in the acidic region was observed only if the samples
were concentrated 40 times, a result indicating that the acidic MMP-9
may be present also in healthy individuals, but at much lower levels
than in RR-MS.
To demonstrate that the acidic forms of MMP-9 in the acidic
region were sialylated, 20 ll of RR-MS sera, enriched by gelatin-
Sepharose affinity chromatography, was subjected to desialylation by
incubation with neuraminidase. As shown in Figure 4B, treatment
with neuraminidase shifted the MMP-9 spots from pI 4.2–4.4 to pI
4.4–6.0. A similar shift of the multimeric forms of MMP-9 towards
the more basic region suggests that these are sialylated too. How-
ever, the pIs of the multimeric forms varied slightly in different sera
(data not shown).
Demonstration of MMP-2 phosphorylation
The pIs and relative levels of the five MMP-2 spots were determined
and are shown in Table 1. In some cases, the number of detected
A B
Fig. 4 Detection of sialylated MMP-9 iso-
forms by 2-DZ and desialylation with
neuraminidase. (A) 2-D zymography (2-
DZ) of 20 ll of a pool of sera obtained
from four active RR-MS patients, after
enrichment (10 9 ) by gelatin-Sepharose
affinity chromatography. (B) Analysis by
2-DZ of the different MMP-9 isoforms
after desialylation of 20 ll of the enriched
(10 9 ) pool of MS sera with neuramini-
dase (0.5 U/ll) for 16 hrs at 37°C. Sialy-
lated forms of MMP-9 were detected for
the acidic forms and the multimeric forms
of MMP-9, but not for NGAL-pro-MMP-9.
The oval box on the top shows a magnifi-
cation of the multimeric forms of MMP-9.
Table 1 2-DZ analysis of MMP-2 and effect of treatment with
phosphatase
Spot
Relative
zymolytic level
pI
Without
phosphatase
After phosphatase
treatment
1 18 5.005 5.129
2 13 5.048 5.175
3 52 5.110 5.228
4 13 5.169 5.276
5 5 5.226 5.330
RR-MS pooled sera, enriched in gelatinases by affinity chromatogra-
phy on gelatine-Sepharose, were incubated (O/N, at 37°C) with alka-
line phosphatase (Sigma-Aldrich), and then analysed by 2-DZ. The
isoelectric point of the digested spots was measured by the Image-
Master2D Elite V. 2002.01 software (Amersham Biosciences).
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MMP-2 spots increased to seven, but the central spot always
remained the most abundant one. As the position of charge variants
of MMP-2 did not change in desialylation experiments, we evaluated
whether MMP-2 spots in clinical samples refer to different degrees of
phosphorylation.
A volume of 20 ll of RR-MS pooled sera, enriched in gelatinases
by affinity chromatography on gelatin-Sepharose, was incubated
(overnight at 37°C) with alkaline phosphatase, and then analysed by
2-DZ. The zymographic patterns of the samples treated with phospha-
tase were similar to those of untreated sera (control), except for the
pI values of the five MMP-2 spots, which exhibited pI values more
basic than those in the untreated control samples. The alterations of
the pIs were in line with partial dephosphorylation.
Identification of NGAL-MMP-9 complex, MMP-2 and 65 kD
MMP-9 by Western blot analysis
The identification of gelatinases was carried out in a 10-fold concen-
trated serum sample from RR-MS patients. The concentrated pool
(40 lg) was subjected to 2-DZ (Fig. 5, left panels), whereas the cor-
responding membranes from the 2-DE gel, were cut and treated with
anti-NGAL Ab (panel A’), anti-MMP-2 (panel B’) and anti-65 kD MMP-
9 4A3 Ab (panel C’), respectively (Fig. 5, right panels). The membrane
treatment with an anti-NGAL antibody was in line with the zymograph-
ic observation of NGAL-MMP-9 complex in MS sera (Fig. 3B). As
shown in Fig. 5C’, the anti-MMP-9 4A3 Ab recognized the two
activated forms of 65 kD and 82 kD of MMP-9.
The 65 kD activation form of MMP-9
It is known that MMP-9, in addition to the activated 82 kD form, has
a 65 kD truncation form. The 65 kD MMP-9 has been relatively
neglected, because 1-DZ and ELISA do not allow distinguishing it
from MMP-2 and other MMP-9 forms, respectively. In particular, in
1-DZ the 65 kD MMP-9 and the 66–68 kD MMP-2 migrate at similar
positions. Only recently, the two enzymes were distinguished by
using ConA Sepharose to separate MMP-2 from the 65 kD MMP-9 on
the basis of their different glycosylation [30].
A A’
B B’
C C’
Fig. 5 Identification of gelatinases by Wes-
tern blot analysis. A pool of sera from 10
patients with inactive RR-MS was used.
For 2-DZ, pooled sera were concentrated
10-fold and 40 lg of total proteins were
applied (left panels). For Western blot
analysis pooled sera were concentrated
40-fold and 160 lg of total proteins were
subjected to 2-DE (right panels). 2-DE
gels were cut and the corresponding
nitrocellulose membranes were treated
with anti-NGAL Ab (A’), anti-MMP-2 Ab
(B’) and Anti-MMP-9 (4A3) Ab, recogniz-
ing the 65 kD and the 82 kD activated
forms (C’). Gel A shows the region with
isoelectric point between pH 5–6.5 and
molecular mass between 200 and 75 kD,
analysed by Western blot in A’; Gels B
and C show the region with isoelectric
point between pH 4–5.5 and molecular
mass between 85 and 55 kD, analysed by
Western blot in B’ and C’, respectively.
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As shown in Figure 6 by 2-DZ, concentration on gelatin-Sepha-
rose of serum samples made it possible to detect, in addition to
MMP-2, an additional series of spots, which were assigned to the
65 kD MMP-9 (Fig. 6A). Chromatography on ConA Sepharose con-
firmed the co-presence of both enzymes in the lower region of the
gel. Panel B shows the zymographic profile of the pass through (non-
adsorbed fraction), corresponding to MMP-2. Panel C is related to the
wash steps. Panel D corresponds to the eluted fraction, shown by
Western blot analysis to be the 65 kD MMP-9 (Fig. 5C, left panel).
Discussion
Matrix metalloproteinases-9 and MMP-2 display a complex variety of
functions in health and disease and this implies also that their regula-
tion might be complex [45]. Structural complexity is related to oligo-
and heteromerization with NGAL, post-translational processing
named activation and truncation, glycosylation (e.g. sialylation) and
phosphorylation. We found that all isoforms of both gelatinases exist
in the form of multiple charge variants, some of which were based on
sialylation (MMP-9) or phosphorylation (MMP-2).
A summary of the complete gelatinase pattern observed in this
study is shown in Table 2. Because of this intrinsic complexity, a sim-
ple assessment of MMPs levels in body fluids is no more sufficient to
understand their role in diseases. When restricting the attention to
MMP-9, assumed to be the most important MMP immune effector
implicated in MS pathogenesis, it is possible to note that it is secreted
as inactive forms (the zymogen pro-MMP-9 multimers and mono-
mers and pro-MMP-9 associated with lipocalin) and its activity is
related to at least two activation forms (the N-terminal truncated
82 kD form; the N- and C-terminal truncated 65 kD form).
The activated isoforms probably have different roles, are more or
less sensitive to endogenous inhibitors and are differently prone to
post-translational modifications. Although it is known that MMP-9
can be either glycosylated, sialylated or nitrosylated, whereas MMP-2
may be phosphorylated, the role of these post-translational modifica-
tions has not been ascertained yet, in particular in MS. This may be
ascribed also to the fact that until now it was technically not possible
to investigate in detail the structural changes that may occur in MMPs
with the limited amounts of clinical samples and the available tech-
niques. The charge variants, described here, conceivably may bind
with different affinities to substrates, receptors, inhibitors and activat-
ing enzymes.
Current methods for detecting MMP mRNAs or proteins are
numerous: monodimensional gelatin zymography (1-DZ); in situ
gelatin zymography; Western blotting; in situ hybridization; quanti-
tative PCR; immunohistochemistry; enzyme-linked immunoassays;
and enzyme activity assays (e.g., using fluorogenic peptide-, radio-
labeled-, and fluorescent dye-linked substrates). With the use of
these approaches, MMPs can be described by activity, mRNA,
protein levels, and expression. However, not one of these tech-
niques can provide direct information on post-translational modifi-
cations of the enzymes and charge variants with similar molecular
masses.
With the use of 2-DZ, it is possible to detect the presence of
charge variants and post-translational modifications leading to micro-
heterogeneity. We revealed, for the first time, the different isoforms
and charge variants of gelatinases present in the sera of MS patients
and HC. Four variants of N-GAL-pro-MMP-9, six of the 65 kD MMP-
9, and several undefined charge variants for the MMP-9 isoforms
were detected, whereas five to seven variants of MMP-2 were
observed. As assessed by 2-D zymography of recombinant MMP-9 or
A B
C D
Fig. 6 2-DZ analysis of gelatinase forms
before and after concanavalin-A-Sepharose
chromatography. 75 ll of a 10 9 concen-
trated pool of sera from two patients
with active RR-MS were subjected to
concanavalin-A-Sepharose chromatogra-
phy as described in the methods. Fractions
obtained were desalted and concentrated
and then analysed by 2-D zymography.
25 ll of samples were loaded on the gels.
(A) concentrated pool before concanavalin-A-
Sepharose chromatography; (B) unbound
fraction (‘pass through’) corresponding to
MMP-2; (C) wash step, with residual MMP-
2; (D) eluted fraction from concanavalin-A-
Sepharose chromatography.
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of human control sera, the presence of charge variants is not
restricted to MS patients and appears to be characteristic of both
MMP-9 and MMP-2. The numbers of variants and their apparent rela-
tive ratios do not change in the pro-forms or in the activation forms.
As shown in http://www.nextprot.org there are 20 variants of MMP-9,
some of these with different pI of the protein.
The second finding reported in this paper is that the multimeric
MMP-9, the pro-MMP-9 and the 82 kD activation form of MMP-9 are
sialylated. Glycan analysis of leucocyte-derived MMP-9 was previ-
ously used to show the presence of core-fucosylated and sialylated
oligosaccharides in human MMP-9 [46].
In the course of MS relapses, all zymolytic MMP-9 spots
increased in intensity and new diffuse spots appeared in the acidic
region of the gel, corresponding to sialylated MMP-9. The increase in
sialylated 82 kD MMP-9 activation form during relapses is because of
its truncation, but also suggests a regulatory role of glycosylation.
With regard to the other activated forms of MMP-9, the 65 kD MMP-
9 does not appear to be sialylated. Sialylation of MMP-9 has been
shown to alter its interaction with TIMP-1 [47].
Serum proteomic analysis has been suggested as an analytical
tool for MS, but has also been found extremely complex in the bio-
marker field. With the present method, we start from a marker, asso-
ciated with MS (e.g. MMP-9) and add information about post-
translational modifications (that also may be associated with MS). In
this way, the information content of MMP-9 as a biomarker for MS
may be reinforced. For instance, further studies should clarify the
causes of the presence of multiple charge variants of gelatinases. At
present, as these enzymes contain a large number of arginines, our
working hypothesis is that, aside protein micro-heterogeneity, the
enzymes may be differentially citrullinated.
It is critical to notice that the serum alterations, observed in this
study, may be the reflection of local alterations of MMPs in the CNS
and be based on changes of MMPs during demyelination or (re)myeli-
nation processes. For example, the relevance of such activities was
expressed in recent publications about myelin-forming and altering
Schwann cell [48, 49]. However, we do not exclude other possible
explanations, such as induction of differentially modified MMP forms
in the liver during inflammations.
Altogether, this work stimulates further investigations into the
roles of MMP isoforms and charge variants in MS, for a better under-
standing of MS pathogenesis, a better evaluation of the response to
therapy and the set up of better diagnostic procedures.
Table 2 Total pattern of different forms of gelatinases detected in MS sera
Gelatinase isoforms Charge variants pI Mw
Gelatinase B (MMP-9) Multimeric form Several (unresolved) 4.2–4.5 >200
NGAL-pro-MMP-9 complex 1 5.61 116
2 5.72 116
3 5.80 116
4 5.92 116
pro-MMP-9 Several (unresolved) 4.1–4.6 90–92
82 kD MMP-9 Several (unresolved) 4.1–4.6 80–82
65 kD MMP-9 1 4.82 65
2 4.86 65
3 4.92 65
4 4.99 65
5 5.06 65
6 5.15 65
Gelatinase A (MMP-2) MMP-2 1 4.97 68
2 5.03 68
3 5.09 68
4 5.16 68
5 5.21 68
Image analysis of 2-DZ was carried out by the ImageMaster2D Elite V. 2002.01 software (Amersham Biosciences).
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Conclusions
In this work, the intrinsic structural complexity of the metalloprotein-
ases MMP-2 and MMP-9 is highlighted. The use of 2-DZ showed not
only the already known MMP isoforms (the pro-forms and the activa-
tion forms of monomers and multimers) but revealed also, for the
first time, a number of charge variants in all isoforms of both
enzymes. In addition, activated 82 kD MMP-9 forms were shown to
be sialylated, whereas activated MMP-2 appeared to be phosphory-
lated. All isoforms and charge variants were observed in concentrated
serum samples without the need to purify the enzymes to homogene-
ity. The structural complexity of MMPs is probably in line with their
numerous functions in physiopathology and must be taken into
account in addition to their regulation by their natural inhibitors TIMPs.
With regard to MS, the aim of this study was to find and to describe
all possible isoforms and isomers (the charge variants with different
pIs, in this study) that can be found in the sera of MS patients.
It was not yet our intention to find any correlation with the course
of the disease or to evaluate the effectiveness of therapy on MMP iso-
form levels. However, with a focus on MMP-9 activated isoforms, we
have found that the C-terminal truncated 65 kD MMP-9 appears only
if the sialylated 82 kD MMP-9 is present and only in MS patients,
whereas the opposite was not observed. These data suggest that the
formation of the truncated 65 kD MMP-9 form is related to an inflam-
matory process. This is also in accordance with knowledge about gly-
cosylation as post-translational modification of proteins [50] and with
the observation that the 65 kD MMP-9 is not inhibited by TIMPs, an
aspect that well correlates with a pathogenetic role.
It is important to note that the 65 kD form cannot be distin-
guished from MMP-2 with classical 1-DZ, whereas this distinction is
possible with the new technique. It may be concluded that because of
their intrinsic complexity, a simple assessment of MMPs levels in
body fluids is no more sufficient to understand their role in disease
pathogenesis.
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